Agressive Blood pressure control with labetalol in patients with brain hemorrhage.

Labetalol infusion to reduce blood pressure variability and hematoma expansion: a randomized control study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009619

Enrollment

110

Registered

2017-09-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute stroke patients admitted to the hospital Health Condition 2: I619- Nontraumatic intracerebral hemorrhage, unspecified

Interventions

Intervention1: intravenous labetalol bolus injection (10-40mg) for a period of 24hours: intravenous labetalol bolus injection (10-40mg) for a period of 24hours Control Intervention1: intravenous labet

Eligibility

Inclusion criteria

Inclusion criteria: 1. First event of intracerebral hemorrhage 2. Symptom onset within 6hours 3. Two consecutive reading of less than 140mmHg 5 mins apart 4. Hematoma volume less than 90ml

Exclusion criteria

Exclusion criteria: 1. COPD / Bronchial Asthma 2. Renal failure with Creatinine clearance of more than 30ml/min 3. Patients with deranged bleeding profile as defined by PT INR > 1.5, PTTK > 45seconds or platelet count

Design outcomes

Primary

Measure	Time frame
1. Hematoma expansion at 24 hours 2. NIHSS at 24 hours Timepoint: 24 hours	—

Secondary

Measure	Time frame
1. Hematoma expansion at 24 hours 2. NIHSS at 24 hoursTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactDr Mahesh Kate

Christan Medical College and Hospital, Ludhiana

maheshpkate@gmail.com9878807951

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026